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Editorial 
Dear Reader 
This 18th issue of Swissmedic Vigilance News 
has been given a new layout: The document 
structure has been simplified, and more con-
trast has been added. These typographical 
and structural changes make the publication 
more accessible and are a further step to-
wards barrier-free communication on drug 
risks. 
Freedom from barriers is something that 
helps both people with disabilities (e.g. visu-
ally or hearing-impaired people or those with 
motor or cognitive disabilities) and older peo-
ple with age-related impairments to receive 
information through the internet without ad-
ditional help. 
Where the use of medicinal products is con-
cerned, it is especially important that both 
medical professionals and patients are able to 
make immediate use of information about 
the relative risks and benefits of, and poten-
tial adverse reactions to, the medicines in 
question – regardless of any disability they 
may have. Swissmedic will continue to work 
on making access to websites and electronic 
documents barrier-free.
The importance of wide-ranging pharma-
covigilance data has been demonstrated time 
and again. The article on “Big Data in Phar-
macovigilance” summarises this situation. 
In our “Signal-Flash”, moreover, we report on 
the systemic use of metronidazole in patients 
with Cockayne syndrome, on new contraindi-
cations for codeine- or dihydrocodeine-con-
taining medicinal products, and on statin-as-
sociated immune-mediated necrotising myo-
pathy. 
Please send any suggestions or feedback on 
this issue of Vigilance News to 
news.vigilance@swissmedic.ch. 
 
The Editors 
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Flash: Drug safety signals 
Cockayne syndrome and metronidazole 
for systemic use: risk of severe 
hepatotoxicity 
Swissmedic is taking the opportunity of this 
communication to inform the healthcare pro-
fessionals concerned about the risks of se-
vere hepatotoxicity with rapid onset after 
the start of treatment with metronidazole for 
systemic use in patients with Cockayne syn-
drome. It is important to specify that metro-
nidazole should be used in these patients af-
ter a careful benefit-risk assessment and only 
if no alternative treatment is available. 
Cockayne syndrome (CS): prevalence, 
aetiology, clinical presentation, prognosis, 
treatment 
Cockayne syndrome (CS) is a rare disease with 
an estimated prevalence in Europe of around 
1 case per 200,000 births. 
CS is a genetic disorder caused by a mutation 
of one of the genes ERCC6 (located on chro-
mosome 10) or ERCC8 (located on chromo-
some 5) and which leads to abnormalities in 
the repair and “decoding” of DNA infor-
mation (transcription). It is associated with 
autosomal recessive transmission. The disease 
can occur equally in boys and girls. 
Cockayne syndrome is clinically characterised 
by growth problems, intellectual impairment 
of varying severity, motor difficulties (neuro-
logical disorders) and impaired vision and 
hearing. Children have a prematurely aged 
face and are extremely thin (cachexia). 
The signs and symptoms are highly variable in 
terms of severity and age of onset.  
The most common form of CS, known as clas-
sical CS (type I) manifests itself during the first 
year of life as delayed growth and neurologi-
cal disorders, followed by a decline in vision 
and hearing. Cases involving an earlier onset 
and with more severe symptoms (type II) such 
as ocular abnormalities and neurological dis-
orders from birth have been described. Fi-
nally, cases with a later onset and more mod-
erate symptoms (type III) have also been re-
ported.  
The cerebro-oculo-facio-skeletal (COFS) syn-
drome corresponds to the extreme prenatal 
form of the clinical spectrum of CS and is char-
acterised by very severe malformations of the 
brain (microcephaly), eyes (microphthalmia 
and cataract) and joints (arthrogryposis).  
Another form of the illness known as Cock-
ayne syndrome also exists – xeroderma pig-
mentosum, which combines all the clinical 
manifestations of Cockayne syndrome with 
an extreme sensitivity of the skin and eyes to 
ultraviolet light (UV), leading to major lesions 
of the skin and an increased risk of skin can-
cer. 
The prognosis varies according to the type of 
CS. Life expectancy is limited, and few people 
suffering from the classical form of the syn-
drome (type I) reach the age of twenty. The 
prognosis is even worse in children with 
type II. By contrast, individuals suffering from 
type III live to adulthood. 
Unfortunately, no treatment capable of cur-
ing patients is available to date. The condition 
is managed symptomatically. 
Metronidazole for systemic use 
Metronidazole, a synthetic nitroimidazole de-
rivative, is active against most strictly anaero-
bic bacteria and also against protozoa. The 
antibacterial and antiparasitic activity of met-
ronidazole is based on the inhibition of the 
synthesis of the nucleic acids of sensitive bac-
teria and protozoa. 
Metronidazole for systemic use is indicated 
for the treatment of infections where the 
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presence of anaerobic bacteria is proven or 
suspected, taking account of metronidazole’s 
spectrum of activity. 
Metronidazole can be used in cases of amoe-
biasis (intestinal or hepatic), urogenital trich-
omoniasis, Gardnerella vaginalis infections 
and giardiasis. 
Risk of severe hepatoxicity 
It is important to note that cases of severe 
hepatotoxicity / acute hepatic failure, includ-
ing cases with a fatal outcome, with rapid on-
set after treatment initiation have been re-
ported in patients with Cockayne syndrome 
taking products containing metronidazole for 
systemic use. In this population metronida-
zole should be used after a careful benefit-
risk assessment and only if no alternative 
treatment is available. Liver function tests 
must be performed prior to the start of ther-
apy, throughout and after the end of treat-
ment until liver function is within normal 
ranges, or until the target values are reached. 
If the liver function test results become mark-
edly elevated during treatment, the drug 
should be discontinued. 
Patients with Cockayne syndrome should be 
advised to immediately report any symptoms 
of potential liver injury to their physician, in-
cluding abdominal pain, anorexia, nausea, 
vomiting, fever, malaise, fatigue, jaundice, 
dark urine, mastic coloured stools or itching, 
and discontinue their metronidazole treat-
ment. 
In contrast, liver injuries have only been de-
scribed very rarely in patients with metroni-
dazole treatment, but without Cockayne syn-
drome. 
Conclusion 
Swissmedic would like to alert healthcare pro-
fessionals who treat patients with Cockayne 
syndrome to the increased risk of severe 
hepatotoxicity after the initiation of metroni-
dazole for systemic use. It is important to 
specify that metronidazole should be used in 
these patients after a careful benefit-risk as-
sessment and only if no alternative treatment 
is available. 
Furthermore, the “Warnings and precau-
tions” section of the product information for 
drugs based on metronidazole for systemic 
use are to be amended to reflect the risk of 
hepatotoxicity described above. 
Reporting suspected adverse drug reactions 
Swissmedic recommends that healthcare pro-
fessionals use its dedicated portal to report 
adverse drug reactions (ADR). This portal, 
which is known as the Electronic Vigilance 
System (ElViS) can be used to directly submit 
ADR. 
All necessary information can be found at 
www.swissmedic.ch > Market surveillance > 
Pharmacovigilance. Reporting undesirable 
side-effects. 
The latest information about medicinal 
products can be found on the Swissmedic 
website: www.swissmedicinfo.ch. 
 
Literature 
(1) B. T. Wilson et al., Metronidazole Toxicity in Cock-
ayne Syndrome: A Case Series, Pediatrics Volume 
136, number 3, September 2015 
(2) B. T. Wilson et al., The Cockayne Syndrome natural 
History (CoSyNH) study: clinical findings in 102 in-
dividuals and recommendations for care, Genetics 
in medicine, Volume 13, Number 5, May 2016 
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Statin-associated immune-mediated 
necrotising myopathy (IMNM) 
General 
The great medical value of statin therapy is 
clear. In their guidelines, the international so-
cieties recommend this substance class as 
highly effective first-line drugs for primary 
and secondary prevention of cardiovascular 
diseases (1). 
Table 1 provides an overview of the statins 
authorised in Switzerland. Use of statins may 
be associated with adverse effects that may 
necessitate discontinuation of the substance 
concerned. The major concern here is a broad 
spectrum of potential adverse drug effects in-
volving the muscles that are associated with 
this substance class. 
They range from mild muscle pain, with or 
without changes in laboratory parameters, to 
serious complications such as the develop-
ment of rhabdomyolysis with acute renal fail-
ure. In most cases, a statin-associated myopa-
thy is self-limiting and ceases when the medi-
cation is discontinued (2). However, an esti-
mated 2 to 3 patients per 100,000 of those 
treated with statins develop a so-called im-
mune-mediated necrotising myopathy 
(IMNM) (3). 
Epidemiology of immune-mediated 
necrotising myopathy (IMNM) 
The statin “exposure time” required for 
IMNM to develop is stated in the literature as 
an average of 2–3 years (4), although this may 
vary greatly from one individual to the next. 
Together with polymyositis, dermatomyositis, 
inclusion body myositis and antisynthetase 
syndrome, IMNM belongs to a subgroup of id-
iopathic inflammatory myopathies (IIM) (5). 
Although there are a few cases of IMNM in 
children, the disease mainly affects adults. It 
is estimated that women are twice as likely as 
men to develop an IIM, although this does not 
apply to statin-associated IMNM. Up to the 
age of 50, women are slightly more at risk 
than men to develop this condition. Above 
this age, there are no gender-specific differ-
ences in its prevalence (6, 7). 
Autoantibodies in IMNM 
Two-thirds of patients with IMNM have spe-
cific autoantibodies (8). Antibodies against 
the signal recognition particle (SRP) were 
identified in this context a long time ago (9). 
The existence of autoantibodies against 3-hy-
droxy-3-methyl-glutaryl-coenzyme A reduc-
tase (HMGCR) that are usually, but not neces-
sarily, found in patients with statin-associated 
IMNM was not discovered until considerably 
later. It is assumed that up to 30 or 40 % of 
IMNM patients have no autoantibodies (8). 
Pathophysiology of IMNM 
The pathophysiology of statin-associated 
IMNM has not definitely been elucidated. 
Anti-HMGCR autoantibodies are directed at 
the catalytic domain of HMGCR, a protein 
found in the membrane of the endoplasmic 
reticulum. Remarkably, HMGCR is involved in 
the biosynthesis of cholesterol and is inhib-
ited by statins (10). It is assumed that statins 
can trigger the development of IMNM by up-
regulating HMGCR expression, hereby trig-
gering an autoimmune response determined 
by certain immunogenetic factors. 
The class II HLA allele DRB1*11:01, present in 
just 10 % of the normal population, has been 
found in 70 % of patients. Regenerating mus-
cle fibres express large quantities of HMGCR. 
This situation, in combination with exposure 
to a statin, ensures a persistently high concen-
tration of this protein and disrupts the bal-
ance between cell decay and repair. Vitamin 
D deficiency is under discussion as a further 
predisposing factor for IMNM (11). 
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Table 1: Statins authorised in Switzerland (1) 
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Contraindication 
ATORVASTATIN 
Sortis® 
Atorvastax® 
10–80 any time, 
independently 
of food 
12 14 61 
high 
CYP3A4 L  Active liver disease or unexplained 
persistent elevation of transaminases 
 Cholestasis 
 Myopathies 
 Pregnancy/breastfeeding 
FLUVASTATIN 
Lescol® 
20–80 prolonged-release 
form: 
any time, independ-
ently of food 
non-prolonged re-
lease form: 
evening, inde-
pendently of food 
20–
30 
<3 34 
(after 24 wk) 
moderate 
CYP2C9 H  Active liver disease or unexplained 
persistent elevation of transaminases 
 Pregnancy/breastfeeding 
ROSUVASTATIN 
Crestor® 
Crestastatin® 
5–40 any time, 
independently of 
food g 
20 19 63 
(after 4 wk) 
high 
only 10 % 
usually into 
N-Desmethyl 
derivative 
H  Active liver disease or unexplained 
persistent elevation of transaminases 
 Severe renal impairment 
(<30 ml/min) 
 Myopathies 
 Concomitant administration of 
ciclosporin 
 Pregnancy/breastfeeding 
PRAVASTATIN 
Mevalotin® 
Pravastax® 
Selipran® 
10–40 any time, 
independently of 
food 
17 3 34 
(after 8 wk) 
low 
 H  Active liver disease or unexplained 
persistent elevation of transaminases 
 Pregnancy/breastfeeding 
SIMVASTATIN 
Zocor® 
Sicora® 
Simvasin® 
20–80 evening, 
independently of 
food 
<5 1.5 53 
moderate 
CYP3A4 L 
Prodrug 
 Active liver disease or unexplained 
persistent elevation of transaminases 
 Concomitant administration of 
potent CYP3A4 inhibitors, 
gemfibrozil, ciclosporin or danazol 
 Pregnancy/breastfeeding 
PITAVASTATIN 
Livazo® 
2–4 any time, 
independently of 
food 
51 12 46.5 
(after 12 wk) 
moderate 
UGT1A3 
UGT2B7 
L  Active liver disease or unexplained 
persistent elevation of transaminases 
 Myopathy 
 Concomitant admin. of ciclosporin 
 Pregnancy/breastfeeding 
Key: low = less than 30 % LDL cholesterol reduction; moderate = 30–49 % LDL cholesterol reduction; 
high = 50 % or more LDL cholesterol reduction; wk = weeks 
References 
(1) Product information Switzerland 
www.swissmedicinfo.ch (cited 21.04.2017) 
Stone NJ, Robinson J, Lichtenstein AH, et al: 2013 
ACC/AHA Guideline on the Treatment of Blood Choles-
terol to Reduce Atherosclerotic Cardiovascular Risk in 
Adults: A Report of the American College of Cardiol-
ogy/American Heart Association Task Force on Practice 
Guidelines. Circulation. 2014; 129 (25 Suppl 2):S1-45. 
 
(2) Micromedex® 1.0 (Healthcare Series), (electronic ver-
sion). Truven Health Analytics, Greenwood Village, 
Colorado, USA. www.micromedexsolutions.com 
(cited 21.04.2017). 
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Histological diagnosis of IMNM 
IMNM is characterised histologically by pro-
nounced muscle fibre necrosis with simulta-
neous muscle fibre regeneration. 
There are only weak, if any, histological signs 
of inflammation (12). Moreover, increased ex-
pression of MHC I on necrotic and non-ne-
crotic muscle fibres and abnormal capillary 
morphology have been found during muscle 
biopsies (13). Clinical studies have shown mac-
rophages that infiltrate the muscle at the his-
tological level to be the dominant type of in-
flammatory cell in anti-HMGCR-positive pa-
tients. 
Moreover, a few CD4- and CD8-positive cells 
and plasmacytoid dendritic cells may some-
times be found in perivascular and endo-
mysial tissue. In contrast, perifascicular atro-
phy and a strikingly large number of B cells – 
of the type generally found in dermatomyo-
sitis – are completely absent in this case (6). 
Compared with other muscle disorders, auto-
antibodies against HMG-CoA reductase are 
predominantly found in biopsy material from 
patients with IMNM. 
Clinical features of IMNM 
IMNM manifests clinically as symmetrical 
proximal muscle weakness of the arms and 
legs, indicative of muscle atrophy/myopathy. 
Disease activity correlates with the measura-
ble and objective muscle strength of the indi-
vidual patient. The onset of the disease may 
be acute (days to weeks) or subacute 
(months). Laboratory testing can show crea-
tine kinase (CK) levels raised many fold up to 
13,000 U/l (normal values: up to 170 in women 
and 190 in men, depending on the laboratory 
method used) (14). 
CK may be (substantially) elevated many 
months previously without the patient expe-
riencing subjective muscle problems (15). To 
this extent, CK is only of limited use as a pa-
rameter of the course of the disease since a 
correlation with muscle strength in the con-
text of IMNM has not yet been demonstrated 
(15). Electromyography (EMG) of affected pa-
tients shows spontaneous electrical dis-
charges (fibrillation potential) and sharply ris-
ing waves (13). MRI imaging shows muscle oe-
dema of the thigh reminiscent of marked, ac-
tive inflammation – a finding that is some-
times at odds with the biopsy (8, 16). 
It is not always only the skeletal muscles of 
the extremities that are affected by IMNM. 
Isolated cases of dyspnoea as a result of re-
striction of the respiratory muscles have been 
described (17). In addition, there have been 
reports of patients with bulbar muscle weak-
ness and symptomatic dysphagia (18). 
Complications of IMNM 
There are indications that statin-associated 
IMNM may be associated with an elevated risk 
of malignant disease (13). Initial studies of 
this aspect have been performed in a number 
of countries. A study in France also compared 
the risk of malignancy in patients with an 
anti-HMGCR-positive myopathy with the risk 
in patients who had an anti-SRP-positive my-
opathy. 
There was a trend towards IMNM patients 
having a higher risk of developing cancer. 
This seems to apply above all to patients in 
whom HMGCR autoantibodies were found 
(23). 
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Table 2: Medical Dictionary for Regulatory Activi-
ties (MedDRA) System Organ Classes (SOC) 
High Level Term (HLT) “muscular autoimmune dis-
orders” with the corresponding Preferred Terms 
(PT) and Lowest Level Terms (LLT) 
 
Muscular autoimmune disorders (HLT) 
» Immune-mediated necrotizing myopathy (PT) 
» Immune-mediated necrotising myopathy (LLT) 
» Immune-mediated necrotizing myopathy (LLT) 
» Inclusion body myositis (PT) 
» Inclusion body myositis (LLT) 
» Sporadic inclusion body myositis (LLT) 
» Juvenile Polymyositis (PT) 
» Juvenile polymyositis (LLT) 
» Morvan syndrome (PT) 
» Morvan syndrome (LLT) 
» Morvan's fibrillary chorea (LLT) 
» Myasthenia gravis (PT) 
» Myasthenia gravis (LLT) 
» Myasthenia gravis aggravated (LLT) 
» Myasthenia gravis paralytica (LLT) 
» Myasthenia gravis crisis (PT) 
» Myasthenia gravis Krise (LLT) 
» Myasthenia gravis neonatal (PT) 
» Myasthenia gravis neonatal (LLT) 
» Neonatal myasthenia gravis (LLT) 
» Myasthenic syndrome (PT) 
» Drug induced myasthenic syndrome (LLT) 
» Eaton-Lambert syndrome (LLT) 
» Lambert-Eaton myasthenic syndrome (LLT) 
» Myasthenia gravis-like paralysis (LLT) 
» Myasthenia gravis-like reaction (LLT) 
» Myasthenia gravis-like syndrome (LLT) 
» Myasthenic syndrome (LLT) 
» Reaction myasthenia gravis-like (LLT) 
» Neuromyotonia (PT) 
» Isaac's syndrome (LLT) 
» Isaacs Syndrom (LLT) 
» Neuromytonia (LLT) 
» Ocular myasthenia (PT) 
» Okulare Myasthenie (LLT) 
» Ocular myasthenia (LLT) 
» Polymyalgia Rheumatica (PT) 
» Polymyalgia rheumatica aggravated (LLT) 
» Rhizomelic pseudopolyarthritis (LLT) 
» Polymyositis (PT) 
» Polymyositis (LLT) 
» Polymyositis haemorrhagica (LLT) 
» Polymyositis hemorrhagica (LLT) 
Differential diagnosis of IMNM and 
extramuscular manifestations 
Probably the most important feature that dis-
tinguishes statin-associated IMNM from a 
conventional statin myopathy is the progres-
sion of the clinical symptoms, even after the 
statin has been discontinued. Unlike other 
forms of IIM – and dermatomyositis and an-
tisynthetase syndrome in particular – extra-
muscular symptoms are rarely dominant in 
IMNM (6). 
In the MedDRA (Medical Dictionary for Regu-
latory Activities) terminology, muscular auto-
immune disorders are classified according to 
Table 2. Yet extramuscular symptoms are also 
described in IMNM patients in the literature. 
Arthralgia and Raynaud’s phenomenon oc-
curred in isolated cases (19). Interstitial lung 
disease can also develop in IMNM patients, 
although this applies more to patients with 
anti-SRP-antibody-positive IMNM. To date, in-
terstitial lung disease has rarely been de-
scribed in patients with an anti-HMGCR anti-
body-associated variant of the disease 
(13, 16). 
Therapy of IMNM 
There are currently no international guide-
lines for the therapy of IMNM. Some patients 
with a statin-triggered autoimmune myopa-
thy and anti-HMG-CoA reductase autoanti-
bodies experienced spontaneous remission 
after statin therapy had ended, without fur-
ther measures. This suggests that, in patients 
with mild symptoms, discontinuation of the 
statins with clinical monitoring of symptoms 
and administration of immunosuppressive 
therapy only as required by the course and 
features of the patient’s condition may also 
be a therapeutic option. In most patients, 
however, immunosuppression in addition to 
discontinuing statin therapy is necessary by 
analogy with other forms of autoimmune 
muscle disease. 
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The therapeutic options that are basically 
available, and often prescribed in combina-
tion, are corticosteroids, e.g. oral prednisone 
1 mg/kg body weight, with other immuno-
suppressive substances (e.g. methotrexate, 
azathioprine, mycophenolate, cyclosporine, 
tacrolimus) and immunoglobulins (IVIG), de-
pending on the severity of the condition (20). 
Studies have also shown immunoglobulins to 
be effective as single-entity therapy, particu-
larly for statin-associated IMNM (21). 
There have been reports of patients who ini-
tially showed progress without any immuno-
suppressive therapy but who subsequently 
derived great benefit from administration of 
IVIG (22). Immunoglobulins can therefore also 
be considered as first-line agents even in spe-
cific patient groups, e.g. those with diabetes.  
There is evidence that many anti-HMGCR pa-
tients initially show only slight improvement 
after administration of prednisone and there-
fore require combination therapy, usually 
with two immunosuppressive agents, before 
an improvement in muscle strength occurs 
and CK values normalise (8). 
However, these patients do tend to relapse 
when immunosuppressive therapy is tapered 
off after the symptoms have improved (12). 
Additional administration of rituximab may 
also have a positive effect on the course of 
the disease. This applies in particular to anti-
SRP-associated IMNM and also to the statin-
associated form of the disease. Moreover, 
plasmapheresis is also recommended in the 
literature as add-on therapy (6, 18, 23). 
Unfortunately, no controlled clinical trials of 
the therapy of IMNM have been performed to 
date. The available data have been generated 
only from clinical experience and case reports. 
Few case reports have been published about 
this special form of myopathy. One of them 
concerned a 59-year-old male patient from 
Switzerland (24). 
It has not been possible to study case series or 
perform cohort studies or even large-scale 
clinical trials because of the small number of 
cases. In a recently published review, four ma-
jor literature databases were searched and a 
total of 16 English-language articles describ-
ing 100 IMNM cases were identified. On aver-
age, the patients were 65 years old, had a 
symmetrical proximal muscle weakness in 
83 % of the cases, and had a mean CK of 6800 
U/l. The majority of the patients received two 
or more immunosuppressants (25). 
Based on the WHO Pharmacovigilance data-
base, Swissmedic is currently cooperating 
with the regional pharmacovigilance centre 
in Zurich to study the largest existing series of 
cases of IMNM. The aim of this analysis is to 
produce a detailed description of this disease 
which occurs rarely during statin therapy. 
 
Swissmedic recently informed healthcare 
professionals about this newly identified 
risk associated with statins (26). It would be 
desirable for physicians to be more alert to 
the risk, particularly in patients over 50 
years of age who are experiencing muscle 
problems on therapy with statins. They 
should bear in mind not only conventional, 
self-limiting statin-associated myopathies 
but also, if muscle pain persists despite dis-
continuation of HMG-CoA reductase inhibi-
tors, an autoimmune cause. In all unclear 
cases, the patient should be tested for 
HMGCR autoantibodies. This test is offered 
as part of myositis screening by specialised 
laboratories. 
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Cough and cold preparations containing 
codeine or dihydrocodeine: Update of 
the product information 
As agreed with Swissmedic, the marketing au-
thorisation holders of cough and cold prepa-
rations containing codeine or dihydrocodeine 
have made updates to the contraindications, 
indication restrictions and other changes to 
the Information for healthcare professionals 
and Patient information. 
Cough and cold preparations containing co-
deine or dihydrocodeine may not be admin-
istered to 
• children below 12 years; 
• patients of any age who are known to be 
"ultra-rapid metabolisers"; 
• breast-feeding women. 
Cough and cold preparations containing co-
deine or dihydrocodeine are not recom-
mended for adolescents between 12 and 18 
years who have problems with breathing. 
Background 
Codeine 
After ingestion, codeine is converted into the 
active metabolite morphine by the hepatic 
isoenzymes CYP2D6, of which several genetic 
polymorphisms are known to exist. 
In some people (known as "ultra-rapid me-
tabolisers"), codeine is converted into mor-
phine faster than normal. 
Since these patients with an "ultra-rapid 
CYP2D6 metaboliser" phenotype have high 
levels of CYP2D6, toxic serum levels of mor-
phine can arise even with small doses and re-
sult in serious complications. The most im-
portant complication is respiratory depres-
sion. 
Other symptoms of overdose include dizzi-
ness, deep sedation, slow or shallow breath-
ing, nausea and vomiting, even cardiac and 
respiratory arrest. 
Although these serious side effects can occur 
in patients of all age groups, a special risk ex-
ists in children below 12 years, since the con-
version of codeine into morphine is more var-
iable and less predictable. 
In breast-feeding mothers who are "ultra-
rapid CYP2D6 metabolisers" and receiving co-
deine treatment, there is a risk of a possibly 
fatal overdose in the baby as a result of re-
ceiving very large quantities of morphine via 
the breast milk.  
If signs of opioid toxicity appear, close moni-
toring of patients is extremely important. 
Consequently, cough and cold preparations 
containing codeine should no longer be ad-
ministered to children below 12 years, pa-
tients of any age who are known to be "ultra-
rapid metabolisers" or breast-feeding 
women. 
Furthermore, codeine is not recommended 
for adolescents between 12 and 18 years with 
impaired respiration since it can lead to symp-
toms of opioid overdose. However, if a cough 
or cold preparation containing codeine is 
used, the patient should be monitored partic-
ularly for symptoms of respiratory depression. 
Dihydrocodeine-containing cough and cold 
preparations 
The contraindications and precautions stated 
for codeine also apply for cough and cold 
preparations containing dihydrocodeine. 
Comparable safety concerns exist for these 
medicinal products, and insufficient experi-
ence has been acquired in the above-men-
tioned risk groups. 
Recommendations for healthcare 
professionals / patients 
Patients taking cough and cold preparations 
containing codeine or dihydrocodeine should 
be monitored for the following symptoms: 
slow or shallow breathing, confusion, drowsi-
ness, constricted pupils, nausea or vomiting, 
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constipation, loss of appetite. If such symp-
toms occur, the administration of the medici-
nal product must be stopped and medical ad-
vice sought immediately. 
The product information (Information for 
healthcare professionals and Patient infor-
mation) for cough and cold preparations con-
taining codeine and dihydrocodeine have 
been modified accordingly. The latest infor-
mation about medicinal products can be 
found on the Swissmedic website: 
www.swissmedicinfo.ch. 
Reporting adverse drug reactions 
Swissmedic recommends to use its dedicated 
portal to report adverse drug reactions (ADR). 
This portal, which is known as the Electronic 
Vigilance System (ElViS), can be used to di-
rectly submit ADR. 
All necessary information can be found at 
www.swissmedic.ch/elvis.
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List of cough and cold preparations containing codeine or dihydrocodeine authorised in 
Switzerland (as of May 2017) 
 
  
Company Preparation Dosage form 
BGP Products GmbH Codein Knoll® Tablets 
DR. BÄHLER DROPA AG Dr. Bähler Bronchialpastillen mit Codein Lozenges 
Coop Vitality Health Care 
GmbH 
Coop Vitality Bronchialpastillen mit 
Codein 
Lozenges 
FARMACEUTICA TEOFARMA 
SUISSE SA 
Paracodin® Drops 
GEBRO PHARMA AG Makatussin Comp., Hustensirup 
Makatussin, Hustentropfen 
Syrup 
Drops 
GSK Consumer Healthcare Resyl® plus 
Tossamin® plus  
Drops, Syrup 
Capsules for the 
day/for the night 
Hänseler AG Husten- und Bronchialsirup «S» mit 
Zucker 
Syrup 
Interdelta SA Néo-Codion® N Film-coated tablets 
Iromedica AG Bronchialpastillen VA mit Codein 
GEM Bronchialpastillen mit Codein 
Iropect® Bronchialpastillen 
MAKU Bronchialpastillen mit Codein 
Pharmacieplus Bronchialpastillen mit 
Codein 
Rotpunkt Apotheke Bronchialpastillen 
mit Codein 
Swidro Bronchialpastillen mit Codein 
Zürcher Bahnhof Apotheke Bronchial- 
pastillen mit Codein 
Lozenges 
Lozenges 
Lozenges 
Lozenges 
Lozenges 
 
Lozenges 
 
Lozenges 
Lozenges 
 
Janssen-Cilag AG Benylin® mit Codein N Syrup 
Streuli Pharma AG Escotussin Drops 
Vifor Consumer Health SA Pectocalmine® N, Sirup 
Pectocalmine® N ohne Zucker, Sirup 
Syrup 
Syrup 
Dr. Heinz Welti AG, Fabrikation 
chemisch-pharmazeutischer 
Produkte 
Codicalm®  
Sano-Tuss N 
Sanotussin 
Syrup 
Syrup 
Film-coated tablets 
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Big Data in Pharmacovigilance – a Synopsis 
Introduction 
The World Health Organization (WHO) de-
fines Pharmacovigilance as “the science and 
activities relating to the detection, assess-
ment, understanding and prevention of ad-
verse effects and all other problems related to 
medicines” (1). 
The scope of pharmacovigilance is complex 
and includes adverse drug reactions (ADR) or 
events, medication errors, counterfeit or sub-
standard medicines, lack of efficacy, misuse 
and/or abuse, and interaction between medi-
cines (see diagram) (2). 
 
 
 
Pharmacovigilance relies heavily on sponta-
neous reporting in which suspected adverse 
drug reactions (ADR) are reported by health 
care professionals, manufacturers or directly 
by patients. Spontaneous reporting systems 
(SRS) provide the highest volume of infor-
mation on patient safety related either to the 
products themselves or to their use. The most 
important function of SRS is early detection 
of safety signals (3).
A signal is defined by the WHO as “Reported 
information on a possible causal relationship 
between an adverse event and a drug, the re-
lationship being unknown or incompletely 
documented previously.” 
While SRS are crucial and essential compo-
nents of pharmacovigilance, they can never 
give a complete picture of patient safety in-
formation. Some of the limitations are (4): 
• The number of reports received cannot be 
used as a basis for determining the inci-
dence of a reaction as neither the total 
number of reactions occurring in the pop-
ulation nor the number of patients ex-
posed to a health product is known. 
• The data collected often have limited pa-
tient information regarding medical his-
tory, concomitant treatment(s), pre-exist-
ing conditions, time to onset, etc.  
• There is underreporting of adverse reac-
tions with both voluntary and mandatory 
surveillance systems, and reporting rates 
may vary widely for drugs as well as for ju-
risdictions. 
• Numerical comparisons cannot be made 
between reactions associated with differ-
ent health products based on the data in 
the line listings. 
• The data reported do not represent all 
known safety information concerning the 
suspected health product(s) and cannot be 
used in isolation to make decisions regard-
ing an individual's treatment regimen; 
other sources of information, including the 
prescribing information for the product, 
should be consulted. 
These limitations force all regulatory agencies 
to find new ways to enhance the quality and 
quantity of ADR, including the use of “big 
data” in pharmacovigilance. 
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What is “Big Data and Analytics”? 
“Big Data” in pharmacovigilance 
Big data refers to a collection of structured 
and unstructured data that may be enor-
mous, in the range of several billion giga-
bytes.  In post-market surveillance, structured 
data may include SRS, electronic health rec-
ords (EHR), electronic medical records (EMR), 
administrative health data (AHD), registries, 
etc.  Unstructured data may include social me-
dia like Twitter, Facebook, patient forums, 
clinical narratives within EMR, etc.  A defini-
tion of big data in post-market surveillance is 
lacking at this time although the EMA refers 
to big data as “an umbrella term describing 
large data sets from any source.” 
Some regulatory agencies, like the United 
States Food and Drug Administration (US 
FDA) (5) and European Medicines Agency 
(EMA) (6) have already considered AHD and 
EMR as part of their post-market surveillance 
systems. Further research is required to 
demonstrate the benefit of using unstruc-
tured data in post-market surveillance. 
While benefits of big data in post-market sur-
veillance are increasingly being recognised, 
its integration and utilisation in the current 
post-market surveillance frameworks requires 
clearly defined objectives, plans, and financial 
resources. 
Relevant Data Sources 
Spontaneous Reporting 
SRS are designed to gather individual case 
safety reports (ICSR) of suspected ADR from a 
variety of sources, including clinicians, phar-
macists, other healthcare professionals, phar-
maceutical companies, medical literature, pa-
tients and the general public. They remain the 
cornerstone of pharmacovigilance; they cover 
all types of drugs used in any setting. Their 
function is to identify potential safety issues 
as soon as possible, and to continuously mon-
itor and evaluate potential safety issues in re-
lation to reported ADR. 
The increase of ICSR in SRS has allowed the 
application of data mining and statistical 
techniques for signal detection. However, the 
success of signal detection in SRS is hampered 
by the concept of voluntary reporting, includ-
ing factors that may influence the reporting 
rate and quality of data, lack of an accurate 
quantification of the frequency of events or 
the identification of possible risk factors for 
their occurrence, and missing denominators.  
To overcome some of these limitations, the US 
FDA (7) and EMA adopted other sources of 
databases including EMR and AHD (8). 
Healthcare System Databases 
Health Care System databases may include 
the following: 
• EHR: Refers to an electronic record of 
health-related information on an individ-
ual that conforms to nationally recognised 
interoperability standards and that can be 
created, managed, and consulted by au-
thorised clinicians and staff across more 
than one health care organisation. These 
are complete health records under the cus-
todianship of a health care provider(s) that 
holds all relevant health information 
about a person over their lifetime. This is 
often described as a person-centric health 
record, which can used by many approved 
health care providers or health care organ-
isations (9). EHR can include all personal 
health information belonging to an indi-
vidual; entered and accessed electronically 
by healthcare providers over the person’s 
lifetime; and extends beyond acute inpa-
tient situations including all ambulatory 
care settings at which the patient receives 
care (10). 
• EMR: Refers to an electronic record of 
health-related information on an individ-
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ual that can be created, gathered, man-
aged, and consulted by authorised clini-
cians and staff within one health care or-
ganisation. These are partial health records 
under the custodianship of a health care 
provider(s) that holds a portion of the rel-
evant health information about a person 
over their lifetime. This is often described 
as a provider-centric or health organisa-
tion-centric health record of a person. EMR 
systems comprise patient information in-
cluding socio-demographic characteristics, 
medical and drug history, diagnostic infor-
mation including laboratory results, treat-
ments and outcomes (11). 
• AHD: This is generated through the rou-
tine administration of health care pro-
grams. These databases include character-
istics of individual members, basic demo-
graphic data, therapeutic procedures, 
treatments and outcomes, diagnoses of 
hospital admissions, reimbursed prescrip-
tions of drugs, etc. 
• Registries: Contain standardised infor-
mation about a group of patients who 
share the same condition or experience. 
Although these databases are designed pri-
marily for routine clinical care they have been 
frequently utilised for observational studies. 
Their representativeness of routine clinical 
care makes it feasible to study real world 
safety data, effectiveness and prescription 
patterns. In addition, these databases have 
been used in pharmacovigilance predomi-
nantly to confirm signals from SRS on an ad 
hoc basis (12). 
Such databases are also an important source 
of data for detection of ADR.  However, ex-
tracting signals from these databases requires 
specific methods to analyse the unique issues 
that arise from working with non–ICSR data. 
Non-conventional Data Sources 
Non-conventional data sources are primarily 
non-structured data that may be used to com-
plement existing SRS. Non-conventional data 
sources include the biomedical literature (in-
cluding amateur press), social media (includ-
ing Twitter, Facebook, patient forums, etc.) 
and web search terms.  Further research is re-
quired to demonstrate the benefit of using 
these data in post-market signal detection. 
Opportunities of big data in 
pharmacovigilance 
Increased interest exists in evaluating big 
data analytics for pharmacovigilance because 
it has the potential to supplement traditional 
spontaneous reporting systems in several 
ways: 
• It could be a cost-effective (re)use of exist-
ing administrative data to enable active 
surveillance. 
• It could provide more timely signal detec-
tion over traditional spontaneous report-
ing systems. 
• It has the potential to complement tradi-
tional systems (such as clinical trials and 
SRS) with real world data, and to use epi-
demiological methods to estimate the inci-
dence of adverse events in populations. 
• It could provide a better way to identify 
and investigate medicine-adverse event as-
sociations that happen over a longer pe-
riod of time (which could be missed by 
spontaneous reporting). 
• It enhances the ability to investigate sig-
nals across different sub-populations and 
to control for confounders. 
Challenges 
While potential benefits of big data in post-
market surveillance have been acknowl-
edged, a number of challenges were high-
lighted as well, particularly with the integra-
tion and utilisation of big data in the current 
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pharmacovigilance framework. The common 
challenges identified include: 
Security and privacy 
• Privacy & legal considerations for sharing 
of data between countries and even be-
tween different national databases or data 
holders. 
Partnerships 
• Building domestic and international part-
nerships to access data sources that are not 
held by the regulator. 
Infrastructure and capacity 
• Building internal capacity to leverage new 
data sources, including both IT infrastruc-
ture and the expertise to use it effectively. 
• Building infrastructure and common data 
models to support datasets and develop in-
novative methods to link together differ-
ent data sources. 
• Resources required to develop, evaluate 
and use data may be substantial and will 
involve multi-disciplinary teams. 
Standards 
• Developing international standards, princi-
ples and best practices for sharing, combin-
ing and validating data from multiple 
sources and databases.  
• Establishing internationally harmonised 
standards to accept results of big data 
analysis by other regulatory agencies. 
• Developing common data models to share 
data. 
• Different coding systems for spontaneous 
AE databases and health care data, need-
ing extraction and mapping of ADR. 
Data analysis 
• Establishing methods and standards to ef-
ficiently evaluate data for secondary uses, 
which may be biased due to a number of 
factors, including practitioner behaviour, 
administrative dataset is mainly for finan-
cial purposes, EMR is primary for clinical 
management. 
• Incomplete data due to partial participa-
tion by healthcare providers (public vs. pri-
vate). 
• Challenges in converting free text data to 
structured data. 
• The rules governing data collection may 
change over time and electronic access to 
historical records may be limited. 
Despite significant recognised challenges, 
various international research projects and 
collaboration programs have already been in-
itiated to explore and to exploit the huge po-
tential and presumed benefits of big data in 
pharmacovigilance. 
Currently, Swissmedic is actively participating 
in collaboration initiatives to build up and 
take advantage of big data analysis as soon as 
such pharmacovigilance systems have been 
established. 
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Regulatory 
Pharmaceutical industry: Back reporting 
of Swissmedic reports 
The regional pharmacovigilance centres re-
ceive reports of adverse drug reactions from 
healthcare professionals and patients, process 
them and then send them to the Swissmedic 
national pharmacovigilance centre, where 
the reports are evaluated once again and for-
warded to the marketing authorisation 
holder(s) of the suspect medicinal product(s). 
Swissmedic would like to take this oppor-
tunity to point out the following: 
• These individual case reports should not be 
sent by the pharmaceutical companies con-
cerned to Swissmedic (“back reporting”), 
since this leads to duplicates by double-re-
porting and causes a considerable amount 
of extra administrative work for all in-
volved. 
• Reports forwarded to pharmaceutical com-
panies by Swissmedic have already been 
medically evaluated. If a pharmaceutical 
company disagrees with this evaluation, 
this is not a reason for sending the report 
to Swissmedic. If Swissmedic wants a phar-
maceutical company's evaluation of a re-
port or situation, a corresponding state-
ment is requested. 
• If a pharmaceutical company possesses rel-
evant follow-up information, this must be 
sent to Swissmedic as a follow-up report 
with reference to the initial report. 
ElViS training courses 
From early 2017 on, the ElViS training courses 
for marketing authorisation holders are not 
being held anymore. The training document 
can be found below: 
www.swissmedic.ch/elvis-training-manual. 
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Information on the Swissmedic website 
(Most of the links are available in German/French only) 
 
Health Professional Communication 
10.05.2017  
DHPC – Keytruda® (Pembrolizumab): Schwere 
Hautreaktionen  
Tödlicher Fall von Stevens-Johnson Syndrom und 
tödlicher Fall von toxischer epidermaler Nekro-
lyse 
 
03.05.2017  
DHPC – Cipralex® (Escitalopram), Seropram® (Ci-
talopram)  
Aufnahme von Rhabdomyolyse als unerwünschte 
Wirkung in die Arzneimittelinformation von Esci-
talopram- und Citalopram-haltigen Arzneimitteln 
 
03.04.2017  
Wichtige Information – Carnitene sigma-tau, In-
jektionslösung  
Produktemangel einer Charge 
 
31.03.2017  
DHPC – Rapifen® Injektionslösung (Alfentanil)  
Rapifen Packungsbeilage – fehlerhafte Tabelle 
 
15.03.2017  
DHPC – Gilenya® (Fingolimod)  
Risiko von Melanom und Lymphom 
 
01.03.2017  
DHPC – Imnovid® (Pomalidomid)  
Neuer wichtiger Hinweis – Hepatitis-B-Virus-Sta-
tus vor Beginn der Behandlung mit Pomalidomid 
abzuklären 
 
11.02.2017  
DHPC – Noxafil® (Posaconazol)  
Noxafil® Tabletten und orale Suspension sind 
nicht austauschbar 
 
27.01.2017  
HPC – Correct use of retinoids in dermatology  
Due to the highly teratogenic potential of retin-
oids, the precautions related to women of child-
bearing age must be followed scrupulously. 
 
18.01.2017  
DHPC – Xarelto® (Rivaroxaban)  
Risiko von Stevens-Johnson-Syndrom und von 
Agranulozytose 
 
21.12.2016  
DHPC – Prolia® (Denosumab)  
Risiko von multiplen Wirbelfrakturen im Zusam-
menhang mit Knochenmineralverlust nach Abset-
zen von Prolia® 
 
01.11.2016  
HPC – Hepatitis E bei Transplantatempfängern  
In Europa werden Hepatitis E Virus (HEV) Infekti-
onen durch Nahrungsmittel beobachtet, und in 
seltenen Fällen auch Übertragungen durch Blut-
transfusionen.  
 
Announcements 
09.05.2017  
Informationsveranstaltung zur Neuausrichtung 
der Zusammenarbeit mit Verbänden und Organi-
sationen der Fach- und Medizinalpersonen  
 
01.05.2017  
Dringliche Änderung der Monographie Erythro-
mycinethylsuccinat in der Europäischen Pharma-
kopöe  
Um einem möglichen Versorgungsengpass auf 
dem europäischen Markt vorzubeugen, wurde 
am 1. Mai eine dringliche Änderung der Europäi-
schen Pharmakopöe in Kraft gesetzt. 
 
10.04.2017  
Simplified self-medication – changes in the way 
medicinal products are dispensed  
 
05.04.2017  
Neuausrichtung der Zusammenarbeit mit Verbän-
den und Organisationen der Fach- und Medizi-
nalpersonen 
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01.04.2017  
Nachtrag 9.1 der Europäischen Pharmakopöe in 
Kraft  
Der Institutsrat hat den Nachtrag 9.1 der Europäi-
schen Pharmakopöe auf den 1. April 2017 in 
Kraft gesetzt. 
 
29.03.2017  
Regierungsrat Lukas Engelberger in den Instituts-
rat von Swissmedic gewählt  
Der Vorsteher des Gesundheitsdepartements des 
Kantons Basel Stadt ersetzt ab dem 1. April Alt-
Regierungsrat Carlo Conti. 
 
24.03.2017  
Adaptation of Information sheet RMP / ICH E2E – 
Information for submissions (available in German 
only)  
Adaptation of Information sheet  
 
14.03.2017  
Swissmedic agrees closer collaboration in thera-
peutic products field with Austrian partner au-
thority  
Press release 
 
07.03.2017  
Illegally imported medicinal products in 2016: 
major risk among prescription-only medicines  
Press release 
 
06.02.2017  
Pyrrolizidine alkaloids in medicinal products  
Risk evaluation and assays required to ensure 
quality and safety 
 
31.01.2017  
Blood donation criteria for men who have sex 
with men: blanket exclusion to be lifted  
Swissmedic has approved an application submit-
ted by Swiss Transfusion SRC 
 
30.01.2017  
News about electronic pharmacovigilance reports  
From 2017, the ElViS training courses are no 
longer being organised. 
 
01.01.2017  
Neue Ausgabe der Europäischen Pharmakopöe in 
Kraft  
Der Institutsrat hat die Ausgabe 9.0 der Europäi-
schen Pharmakopöe auf den 1. Januar 2017 in 
Kraft gesetzt. 
 
22.12.2016  
Swissmedic’s approach to handling EC certificates 
for medical devices  
Swissmedic has decided to follow the harmonised 
European procedure. 
 
19.12.2016  
Swissmedic patient / consumer organisations 
working group  
Pilot to be extended by another two years 
 
14.12.2016  
Adaptation of formal requirements for mark-
ing/highlighting changes in manuscripts of me-
dicinal product information (information for 
healthcare professionals and patient information)  
The new requirements for manuscript presenta-
tion apply to all new submissions made to Swiss-
medic as of 1 January 2017. 
 
01.12.2016  
35 new psychoactive substances added to Narcot-
ics List  
The Federal Department of Home Affairs (FDHA) 
has prompted to add 35 substances to the Nar-
cotics List. 
 
Please find the complete list at the following 
web address: www.swissmedic.ch/updates 
